<DOC>
	<DOCNO>NCT01563354</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , open-label , 3-arm , phase II study single-stage design arm . The purpose study test effectiveness safety Everolimus Pasireotide LAR alone combination adult patient advance ( unresectable metastatic ) neuroendocrine carcinoma ( typical atypical ) lung thymus . It expect total 120 patient 40 patient arm enrol study . Patients disease control ( SD well ) combination arm monotherapy pasireotide LAR everolimus experience unacceptable toxicity permit continue treatment 12 month treatment period extension phase study . Primary Endpoint define proportion patient progression-free 9 month accord RECIST V 1.1</brief_summary>
	<brief_title>3-arm Trial Evaluate Pasireotide LAR/Everolimus Alone/in Combination Patients With Lung/Thymus NET - LUNA Trial</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Histological confirm advanced well differentiated typical atypical carcinoid tumor lung thymus Patients treatment line include naive patient enrol At least one measurable lesion disease CT scan MRI Radiological documentation disease progression within 12 month prior randomization Adequate liver , renal bone marrow function WHO Performance Status 02 Poorly differentiate neuroendocrine carcinoma Nonneuroendocrine thymoma Patients severe functional disease require symptomatic treatment somatostatin analog Prior therapy mTOR inhibitor History liver disease Baseline QTcF &gt; 470 msec Uncontrolled diabetes mellitus despite adequate therapy Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>neuroendocrine carcinoma ; lung ; thymus ; pasireotide LAR ; everolimus</keyword>
</DOC>